Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1615 1617 1622 1626 1637 1793 3783
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18730010 | APATITE FOR FILLER AND FILLER COMPOSITION COMPRISING SAME | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18800224 | PEST CONTROL COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18554928 | OPHTHALMIC FORMULATIONS FOR SUSTAINED NEUROPROTECTION | Non-Final OA | The Johns Hopkins University |
| 19101686 | NANOSTRUCTURE, METHOD OF MANUFACTURING NANOSTRUCTURE, FILM, AND STRUCTURE INCLUDING FILM | Non-Final OA | SONY GROUP CORPORATION |
| 18689457 | SUNSCREEN OR DAILY CARE COMPOSITION COMPRISING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND INORGANIC UV FILTERS | Final Rejection | BASF SE |
| 18250350 | COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT AND TWO POLYGLYCERYL FATTY ACID ESTERS | Final Rejection | L'OREAL |
| 18090154 | Compositions and methods for treating keratin materials | Non-Final OA | L'Oreal |
| 18261512 | WATER-IN-OIL TYPE COMPOSITION | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18210789 | Oral Compositions and Related Methods | Non-Final OA | Colgate-Palmolive Company |
| 18567817 | COMPOSITE OPACIFIER DISPERSION | Final Rejection | Dow Global Technologies LLC |
| 18146499 | MIDAZOLAM PREMIX FORMULATIONS AND USES THEREOF | Non-Final OA | Baxter Healthcare SA |
| 18576593 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | Final Rejection | ELANCO US INC. |
| 18474292 | Implantable Medical Device for the Delivery of a Nucleic Acid | Non-Final OA | Celanese EVA Performance Polymers LLC |
| 18157134 | Method for Prohibiting and/or Treating an Eye Condition | Final Rejection | Celanese EVA Performance Polymers LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy